Lyora Therapeutics raised $2.5 million to advance its pipeline of genetic medicines for the treatment of inherited retinal diseases, including PRPF31-associated retinitis pigmentosa, Usher Syndrome Type 2, and Leber Congenital Amaurosis Type 10.
Investment Amount (In Millions) : 2.5